Alphamab Oncology seeks share repurchase, new share issue mandates
Alphamab Oncology (HKEX:9966) announced that it will seek shareholder approval for general mandates to repurchase shares and issue new shares, including reselling or transferring treasury shares, at its annual general meeting on June 12, 2025. The proposed share repurchase mandate would allow the company to repurchase up to 10% of its issued shares. The proposed new share issue mandate would authorize the company to issue up to 20% of its issued shares. Shareholders will also vote on the re-election of directors Dr. XU Ting, Mr. CHO Man, and Mr. WEI Kevin Cheng, and the re-appointment of Deloitte Touche Tohmatsu as auditors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Alphamab Oncology publishes news
Free account required • Unsubscribe anytime